Loading
Syncromune's treatment, SYNC-T, freezes and breaks down a small part of one tumour and then infuses a mix of immune-stimulating drugs directly into it, aiming to train the immune system to attack cancer throughout the body. It is in a phase 2 trial for advanced prostate cancer that no longer responds to hormone treatment.
Syncromune, Inc., at 2919 East Commercial Boulevard, Fort Lauderdale, Florida, develops the SYNC-T solid tumour immunotherapy platform, a personalised in situ approach that combines partial cryolysis of a small part of a tumour with infusion of a multi-target biologic drug directly into the tumour, designed to address several immune suppression mechanisms at once while stimulating an immune response. Its leadership includes Charles Link, who previously founded NewLink Genetics. The first candidate, SYNC-T Therapy SV-102, is being evaluated in LEGION-100, a phase 2 trial in metastatic castration-resistant prostate cancer, following a phase 1 study for which the company reported long-term data in October 2026 and presented updated overall survival at ESMO 2026. Its first registered cancer trial, NCT06533644 (LEGION-100), was posted on ClinicalTrials.gov in August 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/